Showing results (91-100 of 161) with videos related to

Sort By:
Pageof 17
Gut Microbes|November 18, 2022
Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosisMartin Diebold, Marco Meola, Srinithi Purushothaman, et al.
The Journal of Experimental Medicine|January 12, 2005
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphomaMarkus Krumbholz, Diethilde Theil, Tobias Derfuss, et al.
Neuroimage. Clinical|August 25, 2022
Brain atrophy measurement over a MRI scanner change in multiple sclerosisTim Sinnecker, Sabine Schädelin, Pascal Benkert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 13, 2016
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severityJens Kuhle, Christian Barro, Giulio Disanto, et al.
Brain Pathology (Zurich, Switzerland)|September 6, 2007
Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal gangliaTobias Derfuss, Stephan Segerer, Simone Herberger, et al.
Neurology|May 24, 2013
T-cell response against varicella-zoster virus in fingolimod-treated MS patientsMeret E Ricklin, Johannes Lorscheider, Anne Waschbisch, et al.
Therapeutic Advances in Neurological Disorders|February 6, 2023
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosisIlaria Callegari, Mika Schneider, Vera Aebischer, et al.
Journal of Neurology|June 20, 2012
Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosisKatrin Weier, Andreas Beck, Stefano Magon, et al.
Cell Reports. Medicine|December 22, 2023
B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosisCan Ulutekin, Edoardo Galli, Bettina Schreiner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 14, 2022
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MSNicola de Stefano, Frederik Barkhof, Xavier Montalban, et al.
Pageof 17